Poniard Pharmaceuticals (PARD)
OTHER OTC:PARD
US Market
Holding PARD?
Track your performance easily

Poniard Pharmaceuticals (PARD) Income Statement

8 Followers

Poniard Pharmaceuticals Income Statement

Last quarter (Q ), Poniard Pharmaceuticals's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q, Poniard Pharmaceuticals's net income was $-3.82M. See Poniard Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 10Dec 09Dec 08Dec 07Dec 06
Total Revenue
-$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
-$ 0.00$ 0.00$ 0.00--
Gross Profit
-$ 0.00$ 0.00$ 0.00--
Operating Expense
$ 15.53M$ 26.33M$ 40.44M$ 49.16M$ 35.35M$ 21.23M
Operating Income
$ -15.53M$ -26.33M$ -40.44M$ -49.16M$ -35.35M$ -21.23M
Net Non Operating Interest Income Expense
$ -509.00K$ -2.09M$ -2.74M$ 592.00K--
Other Income Expense
-$ -1.63M$ -2.54M$ 592.00K$ 105.00K$ -330.00K
Pretax Income
------
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -16.23M$ -30.79M$ -46.22M$ -49.06M$ -33.28M$ -23.79M
Basic EPS
$ -12.00$ -26.40$ -52.40$ -56.40$ -43.20$ -54.80
Diluted EPS
$ -12.00$ -26.40$ -52.40$ -56.40$ -43.20$ -54.80
Basic Average Shares
$ 5.55M$ 1.17M$ 881.80K$ 867.15K$ 769.05K$ 434.40K
Diluted Average Shares
$ 5.55M$ 1.17M$ 881.80K$ 867.15K$ 769.05K$ 570.21K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 15.53M$ 26.33M$ 40.44M$ 49.16M$ 35.35M$ 21.23M
Net Income From Continuing And Discontinued Operation
$ -16.04M$ -30.05M$ -45.72M$ -48.56M$ -32.78M$ -23.29M
Normalized Income
$ -16.04M$ -28.43M$ -43.17M$ -48.56M$ -32.89M$ -22.96M
Interest Expense
$ 536.00K$ 2.21M$ 3.14M$ 1.90M--
EBIT
$ -15.53M$ -26.33M$ -40.44M$ -49.16M$ -35.35M$ -21.23M
EBITDA
$ -14.26M$ -25.02M$ -38.97M$ -47.55M$ -34.22M$ -17.02M
Currency in USD

Poniard Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis